Lupin Launches Generic Niaspan Tablets in the US
DSIJ Intelligence / 21 Mar 2014
Pharma Major Lupin announced that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended‐Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) on March 20, 2014.
Pharma Major Lupin announced that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended‐Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) on March 20, 2014.
Lupin’s Niacin Extended‐Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB‐rated generic equivalent of AbbVie Inc.’s Niaspan Tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL‐C, Apo B and TG levels, and to increase HDL‐C patients with primary hyperlipidemia and mixed dyslipidemia.
Niaspan Tablets had annual U.S sales of approximately USD 1 billion (IMS MAT Dec, 2013)
Commenting on the approval, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are happy to launch this product having received approval from the FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market.”
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.